Watch CTMX. Know when insiders buy.
One email the day a filing lands. Free.
CTMX
CytomX Therapeutics, Inc.
3.35
−0.19 −5.37%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $730MP/E —DIV YIELD —FCF YIELD -11.30%REV TTM $18.3M −87.0%NET INCOME −$79.7M −266.0%NET CASH $14.2M52W 1.93 – 6.75SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.4M | −92.4% | — | −$23.8M | −$20.7M | — | — | −$18.1M | $0 | −$18.1M | Aug 6 |
| Q1 2026 · Mar 31 | $10.3M | −79.9% | — | −$19.7M | −$18.2M | −177.6% | — | −$25.5M | $0 | −$25.5M | Aug 6 |
| Q4 2025 · Dec 31derived | $663K | −98.3% | — | −$27.9M | −$26.5M | −240.4% | — | −$23.2M | $201K | −$23.4M | Mar 16 |
| Q3 2025 · Sep 30 | $6M | −82.2% | — | −$15.8M | −$14.2M | −348.1% | — | −$15.5M | −$127K | −$15.4M | Nov 6 |
| Q2 2025 · Jun 30 | $18.7M | −25.7% | — | −$1.3M | −$154K | — | — | −$15.8M | $27K | −$15.8M | Aug 6 |
| Q1 2025 · Mar 31 | $50.9M | +22.8% | — | $22.6M | $23.5M | +70.6% | — | −$21M | $119K | −$21.2M | Aug 6 |
| Q4 2024 · Dec 31derived | $38.1M | +43.2% | — | $17.7M | $18.9M | +2155.2% | — | −$19.9M | $80K | −$20M | Mar 16 |
| Q3 2024 · Sep 30 | $33.4M | +26.7% | — | $4.1M | $5.7M | +91.7% | — | −$20.7M | $19K | −$20.7M | Nov 6 |
| Q2 2024 · Jun 30 | $25.1M | — | — | −$8.5M | −$6.5M | — | — | −$19.5M | $96K | −$19.6M | Nov 6 |
| Q1 2024 · Mar 31 | $41.5M | — | — | $11.7M | $13.8M | — | — | −$26M | $115K | −$26.2M | Nov 6 |
| Q4 2023 · Dec 31derived | $26.6M | — | — | −$606K | $837K | — | — | −$22M | $266K | −$22.2M | Mar 6 |
| Q3 2023 · Sep 30 | $26.4M | — | — | $3.1M | $3M | — | — | −$18.2M | $9K | −$18.3M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $76.2M | — | −$22.4M | −$17.4M | -22.8% | — | −$75.6M | $220K | −$75.8M | — | — |
| FY2024 · to Dec 31 | $138.1M | — | $25M | $31.9M | 23.1% | — | −$86.2M | $310K | −$86.5M | — | — |
| FY2023 · to Dec 31 | $101.2M | — | −$6.5M | −$569K | -0.6% | — | −$56M | $840K | −$56.9M | — | — |
| FY2022 · to Dec 31 | $53.2M | — | −$101.3M | −$99.3M | -186.8% | — | −$110.8M | $1.7M | −$112.5M | — | — |
| FY2021 · to Dec 31 | $37.3M | — | −$116M | −$115.9M | -310.5% | — | −$119M | $1.6M | −$120.6M | — | — |
| FY2020 · to Dec 31 | $68.4M | — | −$80.5M | −$64.8M | -94.7% | — | $5.3M | $2.3M | $3M | — | — |
Every number comes from CytomX Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.